Designing drugs that combat kidney damage
| Autor: | Ana Belen Sanz, Maria Dolores Sanchez-Niño, Laura Rodriguez-Osorio, Marta Ruiz-Ortega, Alberto Ortiz, Cristian González-Guerrero, Catalina Martin-Cleary, Beatriz Fernandez-Fernandez, Adrian M. Ramos |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Nephrology
medicine.medical_specialty Renal function Pharmacology Internal medicine Drug Discovery medicine Animals Humans Molecular Targeted Therapy Renal Insufficiency Chronic Intensive care medicine Cause of death Inflammation Kidney Cell Death urogenital system business.industry Drug Repositioning Acute kidney injury Acute Kidney Injury medicine.disease Fibrosis Nanomedicine Years of potential life lost medicine.anatomical_structure Drug development Drug Design business Kidney disease |
| Zdroj: | Expert Opinion on Drug Discovery. 10:541-556 |
| ISSN: | 1746-045X 1746-0441 |
| DOI: | 10.1517/17460441.2015.1033394 |
| Popis: | Kidney disease remains one of the last worldwide frontiers in the field of non-communicable human disease. From 1990 to 2013, chronic kidney disease (CKD) was the top non-communicable cause of death with a greatest increase in global years of life lost while mortality of acute kidney injury (AKI) still hovers around 50%. This reflects the paucity (for CKD) or lack of (for AKI) therapeutic approaches beyond replacing renal function. Understanding what the barriers are and what potential pathways may facilitate the design of new drugs to combat kidney disease is a key public health priority.The authors discuss the hurdles and opportunities for future drug development for kidney disease in light of experience accumulated with drugs that made it to clinical trials.Inflammation, cell death and fibrosis are key therapeutic targets to combat kidney damage. While the specific targeting of drugs to kidney cells would be desirable, the technology is only working at the preclinical stage and with mixed success. Nanomedicines hold promise in this respect. Most drugs undergoing clinical trials for kidney disease have been repurposed from other indications. Currently, the chemokine receptor inhibitor CCX140 holds promise for CKD and the p53 inhibitor QPI-1002 for AKI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|